KR101896599B1 - 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체 - Google Patents
브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체Info
- Publication number
- KR101896599B1 KR101896599B1 KR1020137030972A KR20137030972A KR101896599B1 KR 101896599 B1 KR101896599 B1 KR 101896599B1 KR 1020137030972 A KR1020137030972 A KR 1020137030972A KR 20137030972 A KR20137030972 A KR 20137030972A KR 101896599 B1 KR101896599 B1 KR 101896599B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- methyl
- mmol
- pharmaceutically acceptable
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(CC(C)(C)C(**1)=CC=C1c(cc1C(CC2*)N*)ccc1N2C(*)=O)C(O)=O Chemical compound C*(CC(C)(C)C(**1)=CC=C1c(cc1C(CC2*)N*)ccc1N2C(*)=O)C(O)=O 0.000 description 2
- VANFMSSIVAQLNC-YCRPNKLZSA-N CC(C)OC(N[C@H](C[C@@H]1C)c2cc(-c3ccc(CC(O)=O)cc3)ccc2N1C(C)=O)=O Chemical compound CC(C)OC(N[C@H](C[C@@H]1C)c2cc(-c3ccc(CC(O)=O)cc3)ccc2N1C(C)=O)=O VANFMSSIVAQLNC-YCRPNKLZSA-N 0.000 description 1
- ONPIQQAMSWXICE-SFHVURJKSA-N CC(N/N=C(/[C@H](CC(OC)=O)N=C(c(cc1)ccc1Cl)c1c2)\Nc1ccc2OC)=O Chemical compound CC(N/N=C(/[C@H](CC(OC)=O)N=C(c(cc1)ccc1Cl)c1c2)\Nc1ccc2OC)=O ONPIQQAMSWXICE-SFHVURJKSA-N 0.000 description 1
- LJLURCPYHXPIQS-MGPUTAFESA-N C[C@@H](C1)N(C(C)=O)c2ccc(B3OC(C)(C)C(C)(C)O3)cc2[C@@H]1Nc(cc1)ncc1C#N Chemical compound C[C@@H](C1)N(C(C)=O)c2ccc(B3OC(C)(C)C(C)(C)O3)cc2[C@@H]1Nc(cc1)ncc1C#N LJLURCPYHXPIQS-MGPUTAFESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1106743.6 | 2011-04-21 | ||
| GB201106743A GB201106743D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
| PCT/EP2012/057111 WO2012143413A1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140025484A KR20140025484A (ko) | 2014-03-04 |
| KR101896599B1 true KR101896599B1 (ko) | 2018-09-07 |
Family
ID=44147335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137030972A Expired - Fee Related KR101896599B1 (ko) | 2011-04-21 | 2012-04-19 | 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9029395B2 (enExample) |
| EP (1) | EP2699550B1 (enExample) |
| JP (1) | JP5840763B2 (enExample) |
| KR (1) | KR101896599B1 (enExample) |
| CN (1) | CN103619820B (enExample) |
| AU (1) | AU2012244759B2 (enExample) |
| BR (1) | BR112013026834A2 (enExample) |
| CA (1) | CA2832763C (enExample) |
| EA (1) | EA022341B1 (enExample) |
| ES (1) | ES2544302T3 (enExample) |
| GB (1) | GB201106743D0 (enExample) |
| IL (1) | IL228707A (enExample) |
| MX (1) | MX338515B (enExample) |
| SG (1) | SG194469A1 (enExample) |
| WO (1) | WO2012143413A1 (enExample) |
| ZA (1) | ZA201307645B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| SMT201900009T1 (it) | 2013-03-14 | 2019-02-28 | Glaxosmithkline Ip No 2 Ltd | Derivati 1-acil-4-ammino-1,2,3,4-tetraidrochinolinici 2,3-disostituiti e loro uso come inibitori del bromodominio |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3105232B1 (en) | 2014-02-10 | 2019-08-28 | Concert Pharmaceuticals Inc. | Substituted triazolobenzodiazepines |
| KR102702503B1 (ko) | 2014-04-23 | 2024-09-05 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| MY187540A (en) | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
| EA031679B9 (ru) | 2014-09-12 | 2019-04-30 | Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед | Производные тетрагидрохинолина в качестве ингибиторов бромодомена |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| KR20170055549A (ko) * | 2014-10-02 | 2017-05-19 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 화합물 |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| PH12021551886A1 (en) | 2016-06-20 | 2023-07-17 | Incyte Corp | Crystalline solid forms of a bet inhibitor |
| US10918647B2 (en) | 2016-07-26 | 2021-02-16 | University Of Southern California | Selective bromodomain inhibition of fungal Bdf1 |
| US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054848A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Thetrahydroquinolines derivatives as bromodomain inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| ES2388434T3 (es) | 2003-11-03 | 2012-10-15 | Glaxo Group Limited | Dispositivo de administración de fluido |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| JP5478262B2 (ja) | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | 抗癌剤 |
| WO2010113498A1 (ja) * | 2009-03-31 | 2010-10-07 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011054851A1 (en) * | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201106750D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2013033270A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
-
2011
- 2011-04-21 GB GB201106743A patent/GB201106743D0/en not_active Ceased
-
2012
- 2012-04-19 KR KR1020137030972A patent/KR101896599B1/ko not_active Expired - Fee Related
- 2012-04-19 WO PCT/EP2012/057111 patent/WO2012143413A1/en not_active Ceased
- 2012-04-19 CA CA2832763A patent/CA2832763C/en not_active Expired - Fee Related
- 2012-04-19 ES ES12716378.0T patent/ES2544302T3/es active Active
- 2012-04-19 US US14/111,580 patent/US9029395B2/en not_active Expired - Fee Related
- 2012-04-19 SG SG2013076146A patent/SG194469A1/en unknown
- 2012-04-19 BR BR112013026834A patent/BR112013026834A2/pt not_active Application Discontinuation
- 2012-04-19 CN CN201280029939.XA patent/CN103619820B/zh not_active Expired - Fee Related
- 2012-04-19 EA EA201391285A patent/EA022341B1/ru not_active IP Right Cessation
- 2012-04-19 JP JP2014505610A patent/JP5840763B2/ja not_active Expired - Fee Related
- 2012-04-19 AU AU2012244759A patent/AU2012244759B2/en not_active Ceased
- 2012-04-19 EP EP12716378.0A patent/EP2699550B1/en active Active
- 2012-04-19 MX MX2013012190A patent/MX338515B/es active IP Right Grant
-
2013
- 2013-10-03 IL IL228707A patent/IL228707A/en active IP Right Grant
- 2013-10-14 ZA ZA2013/07645A patent/ZA201307645B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054848A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Thetrahydroquinolines derivatives as bromodomain inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EA022341B1 (ru) | 2015-12-30 |
| AU2012244759A1 (en) | 2013-10-31 |
| ZA201307645B (en) | 2015-04-29 |
| EA201391285A1 (ru) | 2014-04-30 |
| CN103619820B (zh) | 2015-08-19 |
| BR112013026834A2 (pt) | 2016-12-27 |
| SG194469A1 (en) | 2013-12-30 |
| WO2012143413A1 (en) | 2012-10-26 |
| IL228707A0 (en) | 2013-12-31 |
| EP2699550B1 (en) | 2015-06-10 |
| US9029395B2 (en) | 2015-05-12 |
| AU2012244759B2 (en) | 2016-03-03 |
| GB201106743D0 (en) | 2011-06-01 |
| MX2013012190A (es) | 2014-01-31 |
| KR20140025484A (ko) | 2014-03-04 |
| CA2832763C (en) | 2019-09-24 |
| US20140039006A1 (en) | 2014-02-06 |
| ES2544302T3 (es) | 2015-08-28 |
| MX338515B (es) | 2016-04-20 |
| IL228707A (en) | 2016-09-29 |
| CN103619820A (zh) | 2014-03-05 |
| CA2832763A1 (en) | 2012-10-26 |
| JP5840763B2 (ja) | 2016-01-06 |
| EP2699550A1 (en) | 2014-02-26 |
| JP2014511891A (ja) | 2014-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101896599B1 (ko) | 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체 | |
| JP5926793B2 (ja) | ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体 | |
| JP5905075B2 (ja) | ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 | |
| JP5856673B2 (ja) | ７−（３，５−ジメチル−４−イソオキサゾリル）−８−（メチルオキシ）−１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体 | |
| JP5819840B2 (ja) | ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体 | |
| EP2744809B1 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
| JP5844358B2 (ja) | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 | |
| CN102762569A (zh) | 苯并二氮杂*溴区结构域抑制剂 | |
| HK1193411B (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20210904 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20210904 |